U.S. Vaccines Market Size, Share & COVID-19 Impact Analysis, By Type (Live Attenuated, mRNA, Viral Vectors, Toxoid, and Others), By Route of Administration (Parenteral and Oral), By Disease Indication (Viral Diseases {Hepatitis, Influenza, Human Papillomavirus, Herpes Zoster, and Others}, and Bacterial Diseases {Meningococcal Disease, Pneumococcal Disease and Others}), By Age Group (Pediatrics and Adults), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, and Others), and Country Forecast, 2023-2030

Last Updated: November 17, 2025 | Format: PDF | Report ID: FBI109196

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2019-2030
Base Year	2022
Estimated Year	2024
Forecast Period	2023-2030
Historical Period	2019-2021
Growth Rate	CAGR of 8.2% from 2023 to 2030
Unit	Value (USD Billion)
Segmentation	By Type Recombinant/Conjugate/Subunit Inactivated Live attenuated mRNA Viral Vectors Toxoid Others
	By Route of Administration Parenteral Oral
	By Disease Indication Viral Diseases Hepatitis Influenza Human Papillomavirus Measles/Mumps/Rubella Rotavirus Herpes Zoster Others Bacterial Diseases Meningococcal Disease Pneumococcal Disease Diphtheria/Tetanus/Pertussis Others
	By Age Group Pediatrics Adults
	By Distribution Channel Hospital & Retail Pharmacies Government Suppliers Others